Association of epidermal growth factor receptor and K-Ras mutations with smoking history in non-small cell lung cancer patients

Experimental and Therapeutic Medicine

Volumn 5, Issue 2, 2013, Pages 495-498

  Baykara, Onur ^a   Tansarikaya, Merve ^a   Demirkaya, Ahmet ^a   Kaynak, Kamil ^a   Tanju, Serhan ^b   Toker, Alper ^b   Buyru, Nur ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Epidermal growth factor receptor; K Ras; Non small cell lung cancer; Smoking

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GUANOSINE TRIPHOSPHATASE; K RAS PROTEIN;

ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CODON; FEMALE; HUMAN; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; MUTATION; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SMOKING;

EID: 84871357100     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.829     Document Type: Article

References (41)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156, 2001.
2. Flehinger BJ, Kimmel M, Polyak T and Melamed MR: Screening for lung cancer. The Mayo Lung Project revisited. Cancer 72: 1573-1580, 1993.
3. Strauss GM: Measuring effectiveness of lung cancer screening: from concensus to controversy and back. Chest 112 (Suppl 4): 216S-228S, 1997.
4. Amos CI, Xu W and Spitz MR: Is there a genetic basis for lung cancer susceptibility? Recent Results Cancer Res 151: 3-12, 1999.
5. Wood ME, Kelly K, Mullineaux LG and Bunn PA Jr: The inherited nature of lung cancer: a pilot study. Lung Cancer 30: 135-144, 2000.
6. Kopreski MS, Benko FA, Borys DJ, Khan A, McGarrity TJ and Gocke CD: Somatic mutation screening: identification of individuals harboring K-Ras mutations with the use of plasma DNA. J Natl Cancer Inst 92: 918-923, 2000.
7. Forgacs E, Zöchbauer-Müller S, Oláh E and Minna JD: Molecular genetic abnormalities in the pathogenesis of human lung cancer. Pathol Oncol Res 7: 6-13, 2001.
8. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T and Mitsudomi T: Mutations of the Epidermal Growth Factor Receptor gene in lung cancer: Biological and clinical implications. Cancer Res 64: 8919-8923, 2004.
9. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346, 2005.
10. Chang JW, Liu HP, Hsieh MH, Fang YF, Hsieh MS, Hsieh JJ, Chiu YT, et al: Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients. Lung Cancer 61: 328-339, 2008.
11. Sasaki H, Endo K, Okuda K, Kawano O, Kitahara N, Tanaka H, Matsumura A, et al: Epidermal growth factor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer. JCancer Res Clin Oncol 134: 569-577, 2008.
12. Giaccone G, Gallegos Ruiz M, Le Chevalier T, Thatcher N, SmitE, Rodriguez JA, Janne P, et al: Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 12: 6049-6055, 2006.
13. Bos JL: ras oncogenes in human cancer: a review. Cancer Res. 49: 4682-4689, 1989.
14. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S and Bardelli A: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67: 2643-2648, 2007.
15. Oldenhuis CN, Oosting SF, Gietema JA and de Vries EG: Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer 44: 946-53, 2008.
16. Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, BafaloukosD, Kosmidis P, Papadimitriou CA and Murray S: Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9: 962-972, 2008.
17. Sasaki H, Shimizu S, Okuda K, Kawano O, Yukiue H, Yano M and Fujii Y: Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer. Lung Cancer 64: 295-300, 2009.
18. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, et al: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2: e17, 2005.
19. Hemming AW, Davis NL, Kluftinger A, Robinson B, QuenvilleNF, Liseman B and LeRiche J: Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J Surg Oncol 51: 147-152, 1992.
20. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, et al: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311, 2004.
21. Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, HodaS, McIntosh J, et al: Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 53 (Suppl 10): 2379-2385, 1993.
22. Ciardiello F and Tortora G: EGFR antagonists in cancer treatment. N Engl J Med 358: 1160-1174, 2008.
23. Le Calvez F, Mukeria A, Hunt JD, Kelm O, Hung RJ, TanièreP, Brennan P, Boffetta P, et al: TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res 65: 5076-5083, 2005.
24. Tam IY, Chung LP, Suen WS, Wang E, Wong MC, Ho KK, LamWK, et al: Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 12: 1647-1653, 2006.
25. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
26. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
27. Sugio K, Uramoto H, Ono K, Oyama T, Hanagiri T, Sugaya M, Ichiki M, et al: Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer 94: 896-903, 2006.
28. Tokumo M, Toyooka S, Kiura K, Shigematsu H, Tomii K, AoeM, Ichimura K, et al: The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 11: 1167-1173, 2005.
29. Pham D, Kris MG, Riely GJ, Sarkaria IS, McDonough T, ChuaiS, Venkatraman ES, et al: Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 24: 1700-1704, 2006.
30. Lee YJ, Shim HS, Kang YA, Hong SJ, Kim HK, Kim H, Kim SK, et al: Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with non-small cell lung cancer. J Cancer Res Clin Oncol 136: 1937-1944, 2010.
31. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, et al: Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23: 2513-2520, 2005.
32. Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M and Slattery ML: Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 9: 1193-1197, 2000.
33. Keller JW, Franklin JL, Graves-Deal R, Friedman DB, WhitwellCW and Coffey RJ: Oncogenic KRAS provides a uniquely powerful and variable oncogenic contribution among RAS family members in the colonic epithelium. J Cell Physiol210: 740-749, 2007.
34. Wang JY, Wang YH, Jao SW, Lu CY, Kuo CH, Hu HM, HsiehJS, et al: Molecular mechanisms underlying the tumorigenesis of colorectal adenomas: correlation to activated K-Ras oncogene. Oncol Rep 16: 1245-1252, 2006.
35. Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS and Hainaut P: Tobacco smoke carcinogenesis, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 21: 7435-7451, 2002.
36. Pines G, Köstler WJ and Yarden Y: Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. FEBS Lett 584: 2699-2706, 2010.
37. Schmid K, Oehl N, Wrba F, Pirker R, Pirker C and Filipits M: EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res 15: 4554-4560, 2009.
38. Han SW, Kim TY, Jeon YK, Hwang PG, Im SA, Lee KH, KimJH, et al: Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-Ras mutation, and Akt phosphorylation. Clin Cancer Res 12: 2538-2544, 2006.
39. van Zandwijk N, Mathy A, Boerrigter L, Ruijter H, TielenI, deJong D, Baas P, et al: EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro-and prospective observations in non-small-cell lung cancer. Ann Oncol 18: 99-103, 2007.
40. Massarelli E, Varella-Garcia M, Tang X, Xavier AC, OzburnNC, Liu DD, Bekele BN, et al: KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 13: 2890-2896, 2007.
41. Yamanaka S, Gu Z, Sato M, Fujisaki R, Inomata K, SakuradaA, Inoue A, et al: siRNA targeting against EGFR, a promising candidate for a novel therapeutic application to lung adenocarcinoma. Pathobiology 75: 2-8, 2008.